| Document |
Document Title |
|
WO/2021/001044A1 |
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5'-Chloro-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid alkaline metal sal...
|
|
WO/2020/257940A1 |
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...
|
|
WO/2020/264460A1 |
Compounds of formula I: or a pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein: R1 is a pharmaceutically acceptable polymeric moiety comprising a pharmaceutically acceptable polymer chain such that the carbonyl g...
|
|
WO/2020/262455A1 |
The present invention provides a means for increasing the solubility of even a poorly soluble amino acid without changing to an expensive peptide and also without changing the pH, and is characterized in that at least two kinds of amino ...
|
|
WO/2020/262452A1 |
The present invention addresses the problem of providing a novel hydrogen storage material containing a metal organic structure capable of effectively storing hydrogen. Hydrogen can be effectively stored using a hydrogen storage materi...
|
|
WO/2020/262406A1 |
[Problem] To provide a method for heating anhydrous sodium silicate (cullet), a chelating agent, and water to obtain a sodium silicate aqueous solution and a method for producing a high-purity silica sol using the sodium silicate aqueous...
|
|
WO/2020/262451A1 |
The invention addresses the problem that metal-organic frameworks have conventionally only been produced with terephthalic acids having a limited range of substituents even though the amount and type of gas stored thereby can vary depend...
|
|
WO/2020/262258A1 |
A method for producing a peptide compound including a step that uses a condensed polycyclic aromatic hydrocarbon compound represented by formula (1), a reagent for forming a protecting group that includes the compound, and the compound. ...
|
|
WO/2020/252589A1 |
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic a...
|
|
WO/2020/257716A1 |
Disclosed are cationic lipids which are compounds of Formula (A). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ...
|
|
WO/2020/254337A1 |
The invention concerns new quaternary ammonium compounds with surfactant properties and improved biodegradability.
|
|
WO/2020/251368A1 |
The present invention describes liposome formulations comprising a phospholipid, cholesterol and a fatty acid compound or fatty acid containing compound. Also, various medical uses of the liposome formulation are described.
|
|
WO/2020/251812A1 |
Provided is a method of making ethylenediaminetetraacetic acid (EDTA) comprising the steps: (a) providing a reaction mixture (a) comprising ethylenediamine (EDA) and glycolonitrile (GN), wherein reaction mixture (a) comprises 0% to 0.1% ...
|
|
WO/2020/248042A1 |
A liquid composition for use as a consumable stimulant; it has a consumable liquid solvent comprising water; caffeine at a concentration of at least 0,04 g / mL once dissolved in the consumable liquid solvent; and a tyrosine-based compou...
|
|
WO/2020/252336A1 |
These compounds are amino acid transporter inhibitors. Amino acid transporter inhibitors are useful to treat a variety of diseases disorders, or conditions including cancer.
|
|
WO/2020/251613A1 |
There is disclosed a process for the production of dodecanedioic acid and 11- aminoundecanoic acid, comprising: (1) reacting castor oil with a primary or secondary amine to form a amide; (2) isomerizing the amide in the presence of a cat...
|
|
WO/2020/247853A1 |
This invention provides for synthesis of citrulline from a transition metal complex of ornithine using cyanate to derivatize the terminal amino group of ornithine. The invention also provides improved methods for purification of citrulli...
|
|
WO/2020/232597A1 |
The present invention provides a diamine compound, a preparation method therefor, and a thermosetting resin composition. The diamine compound has a structure as represented by structural formula (I). The structure of the diamine compound...
|
|
WO/2020/233651A1 |
Provided are an siRNA which inhibits purine nucleoside phosphorylase (PNP) gene expression, a pharmaceutical composition containing the siRNA, and an siRNA conjugate, capable of effectively treating and/or preventing abnormal uric acid m...
|
|
WO/2020/232542A1 |
The present disclosure relates to carbon dots, uses thereof and methods of manufacture thereof. For example, such carbon dots can be used in the production of biofuels such as biodiesel. For example, these carbon dots can be used as cata...
|
|
WO/2020/232304A1 |
Provided are compositions and methods that comprise the use of abscisic acid and L-arginine to improve foraging activity relative to the pollination performance of bees, and a composition to administer to bees containing abscisic acid an...
|
|
WO/2020/232227A1 |
The present invention provides methods for treating cancer. The present disclosure provides methods of treating cancer by increasing the oxidative stress on the cancer cell. In particular, the present disclosure is directed to methods of...
|
|
WO/2020/220963A1 |
The present invention relates to the field of surfactants. Disclosed are a novel photodegradable amphiphilic molecule and synthesis method therefor. The synthesis of the photodegradable amphiphilic molecule has five steps of reactions: (...
|
|
WO/2020/219876A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/215895A1 |
The present invention relates to the technical field of medicine, and relates to derivatives represented by formula 1 and formula 2 in which a carboxylic acid group is introduced into the structure of ginkgolide B by means of a hydroxyl ...
|
|
WO/2020/212901A1 |
Disclosed are compounds having the following formula (I): Formula (I) wherein R is an alkylene chain having between 8 and 20 carbon atoms, and A is one or more anions having a total charge of -2, or R is a quaternary amine having the fol...
|
|
WO/2020/212399A1 |
The present invention relates to a method for the preparation of the preparation of ethyl (2S, 3S)-3-aminobicyclo [2.2.2] octane-2 -carboxylate from the β-keto ester (II) via a chiral transfer hydrogenation reaction in the presence of a...
|
|
WO/2020/212585A1 |
This invention relates to a process for producing cyanoacetates using aspartic acid as a precursor.
|
|
WO/2020/210485A1 |
Disclosed are processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carbo
xamide, and intermediates for use in said processes along with processes for prepari...
|
|
WO/2020/210486A1 |
The disclosure provides processes for preparing α-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxami
de, as well as intermediates for use in said processes.
|
|
WO/2020/206234A1 |
Disclosed are enantiomerically pure cyclopentane-based compounds that are prepared by a multiple-step synthesis process. The disclosed compounds have been designed to inhibit gamma-aminobutyric acid - amino transferase (GABA-AT) activity...
|
|
WO/2020/193681A1 |
The present invention relates to derivatives of 10-methylene lipids, their preparation and their use.
|
|
WO/2020/188478A1 |
The invention relates to rigidified pentadentate chelating agents of Formulae (I) and (II), which are useful for the [Al18F]2+ labelling of biomolecules. The chelating agents of the invention are used to form coordination complexes with ...
|
|
WO/2020/183376A1 |
The present invention relates to an economical, enzyme catalyzed and commercially viable greener process for manufacturing Pregabalin of formula (I) in high yield with highchemical and chiral purity.
|
|
WO/2020/184336A1 |
Provided is a liquid metal complex having oxygen-absorbing ability and containing: a cobalt acacene complex or a derivative thereof; and an ionic liquid in which an ionic ligand having an amine structure and a counter ion thereof are pai...
|
|
WO/2020/184142A1 |
[Problem] To provide a compound which has high stability with respect to heat, high voltage holding ratio if used in a liquid crystal display element, and the like. [Solution] A compound which is represented by formula (1). In the formul...
|
|
WO/2020/181276A1 |
The invention described herein includes a self-neutralizing amino acid-based cationic composition that contains an amino acid-based cationic ester, a nonionic amphiphile, and an anhydrous buffering agent. In an embodiment, the compositio...
|
|
WO/2020/181207A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to small molecule compounds having bicyclic and tetracyclic quinone scaffolds which have antiproliferative activities through, for example, induc...
|
|
WO/2020/179817A1 |
[Problem] To provide a purification method that enables purification of a diamine compound to which none of purification methods by distillation, sublimation, or recrystallization are applicable, and that, as another purpose of the metho...
|
|
WO/2020/176511A1 |
Disclosed are compound and methods of using the compounds for modulating ornithine aminotransferase (OAT) activity. The disclosed compound are characterized as analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-l-carboxylic acid which ...
|
|
WO/2020/170388A1 |
To provide a novel production promoter of type I collagen or elastin. A production promoter of type I collagen or elastin that comprises a mycosporine-like amino acid or a salt thereof as an active ingredient.
|
|
WO/2020/171636A1 |
The present invention relates to an antibacterial composition against Staphylococcus aureus and Mycobacterium tuberculosis. The composition represented by chemical formula 1 can have excellent antibacterial activity against Staphylococcu...
|
|
WO/2020/162156A1 |
The present invention provides a compound which enables a light emitting element to have excellent luminance life. A compound which is represented by formula (1). (In the formula, n represents an integer of from 2 to 20 (inclusive); ...
|
|
WO/2020/155953A1 |
Provided are a fused tricyclic deuterated derivative, a composition and the use thereof. Particularly, provided are a fused tricyclic deuterated derivative as shown in general formula (I) or a stereoisomer, solvate, metabolite, pharmaceu...
|
|
WO/2020/159399A1 |
The invention relates to the field of the chemical industry, particularly to the synthesis of chemical compounds, and concerns improving a method of producing biologically active forms of mixtures of complex compounds of essential micron...
|
|
WO/2020/157953A1 |
[Problem] To provide a polyimide compound having high heat resistance and transparency. [Solution] The polyimide compound of the present invention is characterized by being the reaction product of a diamine compound represented by genera...
|
|
WO/2020/159587A1 |
Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The stru...
|
|
WO/2020/154891A1 |
The present invention provides a hydrolysis method of tert-butyl ester used in a gadolinium contrast agent. The hydrolysis method comprises the following steps: hydrolyzing the tert-butyl ester by using a catalyst; a preparation method f...
|
|
WO/2020/155952A1 |
The present invention provides a preparation method for a fused tricyclic derivative and an intermediate. The fused tricyclic derivative has a structure represented by formula (I). In the preparation method, raw materials are easy to obt...
|
|
WO/2020/159967A1 |
The present disclosure is directed to an all-optical excitonic switch comprising one or two oligonucleotides that comprises in turn donor/acceptor chromophores and photochromic nucleotide and is assembled with nanometer scale precision u...
|
